Ticker

The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, markedly reduced the…

Basel, 02 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, markedly reduced the annualised relapse rate (ARR) by 51% compared to…

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 2,782,461 shares, a decline of 40.6% from the January 29th total of 4,684,288 shares. Based on an average daily volume of 5,239,296 shares,

David Roche of Quantum Strategy explains why he believes Iran's current regime could fall within a year. He also says he does not see Tehran conceding to U.S. demands to limit its nuclear program, viewing those demands as a threat to national sovereignty.